Levofloxacin Patent Expiration
Levofloxacin was first introduced by Janssen Pharmaceuticals Inc
Levofloxacin Patents
Given below is the list of patents protecting Levofloxacin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Levaquin |
US6806256 (Pediatric) | Taste masked liquid pharmaceutical compositions |
Aug 26, 2022
(Expired) | Janssen Pharms |
| Levaquin | US6806256 | Taste masked liquid pharmaceutical compositions |
Feb 26, 2022
(Expired) | Janssen Pharms |
Levofloxacin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Levofloxacin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) | University of Manitoba | NA |
NOT YET RECRUITING
(Jun 1, 2026)
| PHASE2 |
| A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis | Seoul National University Hospital | NA |
NOT YET RECRUITING
(Jun 1, 2026)
| PHASE3 |